8-K: AMS Reports Q4/FY25 Loss, Debt Covenant Breach

American Shared Hospital Services reported a net loss for Q4 and Full Year 2025, alongside a significant cash decrease and a breach of debt covenants, despite operational expansions.

Summary

• Total revenue for Full Year 2025 was $28.1 million, a slight decrease from $28.3 million in 2024.
• The company reported a net loss attributable to American Shared Hospital Services of $(1.6) million, or $(0.23) per diluted share, for Full Year 2025, compared to net income of $2.2 million, or $0.33 per diluted share, in 2024.
• Fourth quarter 2025 revenue decreased 14.8% to $7.7 million from $9.1 million in the prior year period.
• Gross margin for Full Year 2025 was 18% ($5.1 million), down from 32% ($9.2 million) in 2024, primarily due to increased operating costs from the shift to lower-margin direct patient care services.
• Adjusted EBITDA for Full Year 2025 was $5.5 million, a decrease from $8.9 million in 2024.
• Cash and cash equivalents, including restricted cash, decreased to $3.7 million as of December 31, 2025, from $11.3 million at December 31, 2024, driven by $7.5 million in capital expenditures.
• The current portion of long-term debt, net, was approximately $17.3 million as of December 31, 2025.
• The company did not meet certain financial covenants under its credit facility as of December 31, 2025, and is in discussions with its lender for waivers and/or amendments.
• Shareholders' equity (excluding non-controlling interests) decreased to $24.0 million, or $3.66 per outstanding share, from $25.2 million, or $3.92 per outstanding share, at December 31, 2024.
• LINAC revenue increased 35.4% year-over-year to $11.5 million, while Gamma Knife revenue decreased 5.5% to $9.2 million and Proton Beam Radiation Therapy (PBRT) revenue decreased 26.0% to $7.4 million for Full Year 2025.
• Direct patient care services revenue increased 23.7% to $15.5 million for Full Year 2025, representing 63% of total sales in Q4 2025.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative report due to the significant financial underperformance, including a net loss, declining margins, and a critical debt covenant breach, which overshadows operational expansions and lease extensions.

Positives

• Secured a seven-year lease extension for the Proton Beam Radiation Therapy System with Orlando Health, Inc., through 2033, highlighting long-term partnerships.
• Successfully integrated Rhode Island radiation therapy treatment centers and completed the first full year of operations at the Puebla, Mexico center, expanding the direct patient care services footprint.
• LINAC treatment volumes remained strong, increasing 35.4% year-over-year for Full Year 2025.
• Same-center Gamma Knife procedure volumes improved following equipment upgrades at three sites, and the Gamma Knife unit in Lima, Peru was upgraded to the Esprit platform.
• Received Certificate of Need approvals for a new radiation therapy treatment center in Bristol, Rhode Island, and a proton beam radiation therapy treatment center in Johnston, Rhode Island, indicating future expansion potential.

Negatives

• Reported a net loss of $(1.6) million for Full Year 2025, a significant decline from net income of $2.2 million in 2024.
• Total revenue for Full Year 2025 slightly decreased by 0.9% to $28.1 million.
• Gross margin significantly declined to 18% for Full Year 2025 from 32% in 2024, primarily due to the shift to lower-margin direct patient care services and increased operating costs.
• Adjusted EBITDA decreased to $5.5 million for Full Year 2025 from $8.9 million in 2024.
• Cash and cash equivalents decreased substantially by $7.5 million to $3.7 million as of December 31, 2025.
• Did not meet certain financial covenants under its credit facility as of December 31, 2025, necessitating discussions with its lender for waivers or amendments.
• The leasing segment experienced headwinds from the expiration of three Gamma Knife agreements and lower proton therapy volumes, leading to a 33.9% decrease in leasing revenue for Q4 2025 and a decline for the full year.
• PBRT procedures declined 21% year-over-year, totaling 4,056 in fiscal year 2025 compared to 5,139 in fiscal year 2024.

Risks

• Risks of economic and market conditions affecting financial performance.
• Risks of variability of financial results between quarters.
• Risks inherent in the Gamma Knife, proton therapy, and direct patient care services businesses.
• Risks of changes to CMS reimbursement rates or reimbursement methodology.
• Risks related to the timing, financing, and operations of the company's Gamma Knife, proton therapy, and direct patient care services businesses.
• Risk of expanding within or into new markets.
• Risk that the continued operation of acquired businesses could adversely affect financial results.
• Risk that current and future acquisitions may negatively affect the company's financial position.
• Risk associated with not meeting certain financial covenants under the credit facility, potentially leading to adverse actions by the lender if waivers or amendments are not secured.

Future Outlook

The company remains focused on optimizing operations at existing centers, expanding patient access to advanced radiation therapy treatment options, and pursuing strategic opportunities to strengthen both equipment leasing and direct patient care services segments. Management anticipates additional revenue contributions from the new Esprit at the Guadalajara, Mexico Gamma Knife center and is actively working on expanding its Rhode Island footprint with new treatment centers in Bristol and Johnston, aiming for long-term growth in 2026 and beyond.

Management Comments

• Gary Delanois, CEO: "2025 was a year of transition and operational expansion for American Shared Hospital Services. We successfully integrated the Rhode Island radiation therapy treatment centers and completed the first full year of operations at our radiation therapy treatment center in Puebla, Mexico."
• Gary Delanois, CEO: "While the leasing segment experienced headwinds from the expiration of three Gamma Knife agreements and lower proton therapy volumes, we continued to see encouraging growth at our existing treatment sites."
• Gary Delanois, CEO: "We are extremely pleased to announce a seven-year lease extension with Orlando Health, Inc., for our Proton Beam Radiation Therapy System, a valued partner in advancing access to cutting-edge cancer care."
• Ray Stachowiak, Executive Chairman: "Our strategic shift toward direct patient care services strengthens our long-term growth potential and creates more stable revenue streams."
• Ray Stachowiak, Executive Chairman: "Our Certificate of Need approvals for the first radiation therapy treatment center in Bristol, Rhode Island, where permitting activities are underway and a proton beam radiation therapy treatment center in Johnston, Rhode Island, put us on track to further expand our Rhode Island footprint and growth potential."
• Scott Frech, CFO: "We remain focused on driving revenue growth and anticipate additional contributions from the new Esprit at our Guadalajara, Mexico Gamma Knife center."
• Scott Frech, CFO: "Additionally, we are proactively optimizing our balance sheet and strategic flexibility with ongoing discussions with our lender."
• Scott Frech, CFO: "Additionally, our market value highlights a steep discount to our underlying shareholders' equity of $3.66 per share."

Industry Context

StockSavvy.ai notes that American Shared Hospital Services' strategic shift towards direct patient care services aligns with a broader industry trend in healthcare to control the patient experience and capture more value across the treatment continuum. While the expansion of LINAC services and new facility approvals are positive, the significant decline in PBRT and Gamma Knife leasing revenue, coupled with overall financial losses, suggests challenges in adapting to market dynamics and competitive pressures within the specialized radiation therapy equipment leasing sector. The company's focus on long-term partnerships, as evidenced by the Orlando Health lease extension, is crucial in a capital-intensive industry.

Comparison to Industry Standards

• The decline in PBRT procedures by 21% (4,056 in FY25 vs. 5,139 in FY24) is attributed by the company to 'normal cyclical fluctuations in patient volumes that the healthcare industry experiences from time to time.' This suggests that while the company's PBRT volumes are down, it views this as a broader industry trend rather than a company-specific issue, though no specific comparable companies or projects are named to benchmark this claim.
• The shift to direct patient care services, while strategically sound for long-term growth and stable revenue streams, has resulted in lower gross margins (18% in FY25 vs. 32% in FY24) compared to the equipment leasing segment. This margin compression is a common challenge for companies transitioning business models, especially in healthcare where direct patient care often involves higher operational overheads than pure equipment leasing.

Stakeholder Impact

• Shareholders: Experience a decrease in shareholders' equity and a net loss, potentially impacting share price and future returns. The market value is noted to be at a steep discount to underlying shareholders' equity.
• Creditors: The breach of financial covenants under the credit facility creates uncertainty and requires negotiation, potentially impacting the terms of existing debt.
• Employees: Operational expansion in direct patient care services and new facility approvals could lead to job creation or stability in those segments, though overall financial performance may create pressure.
• Customers/Patients: Expansion of direct patient care services and equipment upgrades (e.g., Gamma Knife Esprit) aim to improve treatment capabilities and patient access to advanced cancer care.

Next Steps

• Continue optimizing operations at existing centers.
• Expand patient access to advanced radiation therapy treatment options.
• Pursue strategic opportunities to strengthen both equipment leasing and direct patient care services segments.
• Anticipate additional contributions from the new Esprit at the Guadalajara, Mexico Gamma Knife center.
• Engage in ongoing discussions with the lender to secure waivers and/or amendments for financial covenants.
• Proceed with permitting activities for the new radiation therapy treatment center in Bristol, Rhode Island.
• Develop a proton beam radiation therapy treatment center in Johnston, Rhode Island.

Key Dates

Recommendation

The company's shift from net income to a significant net loss, coupled with substantial declines in gross margin and Adjusted EBITDA, indicates severe financial deterioration. The critical breach of debt covenants, a significant decrease in cash, and a reduction in shareholders' equity present immediate and serious risks to the company's financial stability. While operational expansions and a key lease extension offer some long-term potential, the current financial distress and uncertainty surrounding debt restructuring make this a high-risk investment. A seasoned investor would likely recommend a strong sell to mitigate exposure to these significant financial headwinds.

Keywords

radiation therapy, cancer treatment, proton therapy, Gamma Knife, LINAC, medical equipment leasing, direct patient care, financial results, SEC filing, healthcare services, debt covenants